OCP Pretreatment in PCOS Patients Undergoing ICSI Using Antagonist Protocol

NCT ID: NCT03881904

Last Updated: 2019-03-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 740 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-01
• Study Completion Date: 2019-07-01

Brief Summary

373 women with PCOS undergoing a trial of IVF/ICSI will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Another 373 women with PCOS undergoing a trial of IVF/ICSI will start GnRH antagonist COH directly without OCP pretreatment.

Both groups will be followed up for effect on ongoing pregnancy rate.

Detailed Description

The study will include 740 women with polycystic ovary syndrome undergoing IVF/ICSI cycle using flexible antagonist protocol.

Randomization:

Patients fulfilling the inclusion criteria will be randomized to two groups.

Study Group:

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Control Group:

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.

Random allocation sequence generation:

A computer generated list via MedCalc ® Software, version 13.2.2 will be used, assigning each participant number to either study groups.

Allocation Concealment:

Assignment will be done by sequentially numbered, otherwise identical, sealed envelopes (SNOSE), each containing a 2-inch by 2-inch paper with a written code designating the assigned group. These papers will be placed in a folded sheet of aluminum foil fitted inside the envelope. Effort will be taken to assure absence of any detectable differences in size or weight between intervention and control envelopes. Envelopes will be chosen to be opaque and lined inside with carbon paper. Envelopes will be opened sequentially only after writing the subject's tracking information on the envelope so that the carbon paper served as an audit trail.

IVF/ICSI cycle will be done using flexible anatgonist protocol in both groups.

Primary outcome will be ongoing pregnancy rate.

Secondary outcomes will be biochemical and clinical pregnancy rates.

Conditions

Subfertility, Female

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

OCP Group

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.

Group Type: ACTIVE_COMPARATOR

0.075mg gestodene/0.03mg ethinylestradiol

Intervention Type: DRUG

OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.

Control Group

This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

0.075mg gestodene/0.03mg ethinylestradiol

OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.

Intervention Type: DRUG

Other Intervention Names

Gynera®

Eligibility Criteria

Inclusion Criteria

1. Age 18-39 years of age.

2. BMI 18-29 Kg/m2

3. Polycystic ovary syndrome, diagnosed - according to the revised 2003 consensus on diagnostic criteria of polycystic ovary syndrome by the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group - by the presence of two of the following three diagnostic features:

1. Oligo- or anovulation [defined as fewer than eight episodes of menstrual bleeding per year or menses that occur at intervals greater than 35 days].

2. Clinical hyperandrogenism [defined by the presence of hirsutism (assessed by a modified Ferriman-Gallwey score ≥ 8), acne or androgenic alopecia] and/or biochemical signs of hyperandrogenism [defined by elevated free androgen index]

3. Polycystic ovaries [defined as presence of 12 or more follicles in each ovary measuring 2 - 9 mm in diameter, and/or increased ovarian volume > 10 mL) in the early follicular phase (cycle days 3 - 5) in regularly menstruating women. Oligo-/amenorrhoeic women should be scanned either at random or between days 3 and 5 after a progestin-induced withdrawal bleeding. This definition does not apply to women taking oral contraceptive pills, since their use modifies ovarian morphology in normal women and putatively in women with PCO.

After exclusion of other etiologies (congenital adrenal hyperplasia, androgen secreting tumors, Cushing's syndrome, hypothyroidism and hyperprolactinemia).

4. Normal transvaginal ultrasonography apart from polycystic ovaries (see before).

5. Normal office hysteroscopy.

6. Normal hysterosalpingography.

7. Absence of any structural pathological findings in laparoscopy apart from enlarged sclerotic polycystic ovaries.

8. Normal hormonal profile (apart from hormonal abnormalities associated with PCOS), e.g. normal thyroid function tests

9. Normal parameters of male semen analysis according to WHO criteria 2010.

10. First trial IVF/ICSI.

11. Written and signed informed consent by the patient to participate in the study.

Exclusion Criteria

1. Age more than 39 years.

2. BMI more than 29 Kg/m2

3. Abnormal ultrasonographic finding, e.g. endometrial polyps, fibroids or ovarian cysts.

4. Abnormal hysteroscopic finding, e.g. endometrial polyps, endometrial hyperplasia or fibroid.

5. Abnormal hysterosalpingographic finding, e.g. hydrosalpinx or peritoneal adhesions.

6. Abnormal male or female karyotyping.

7. Abnormal endocrinological profile during ovarian stimulation not attributed to PCOS, e.g. hypothyroidism, FSH > 12 mIU/mL on day 3.

8. Previous trials of IVF/ICSI.

9. Positive anticardiolipin antibodies or lupus anticoagulant.

10. Positive thrombophilia screen.

11. Abnormal semen analysis parameters according to WHO criteria 2010.

12. Any hormonal treatment within the last 3 months.

13. Any treatment for insulin resistance within the last 3 months, e.g. metformin or leptin.

14. Any chronic medical disorder, e.g. hypertension, autoimmune disorders, … etc.

15. Any category 4 medical condition that contraindicates the usage of OCP according to the WHO Medical eligibility criteria, 2015:

• Smoking with age ≥ 35 years and cigarettes ≥ 15 /day.
• Hypertension (systolic ≥ 160 mmHg or diastolic ≥ 90 mmHg).
• Hypertension with vascular disease.
• Previous history or acute DVT/PE.
• Any known thrombogenic mutations.
• Complicated valvular heart disease.
• Systemic lupus erythematosus with positive or unkown antiphospholipid antibodies.
• Migraine with aura.
• Diabetes with nephropathy/neuropathy/retinopathy.
• Diabetes > 20 years.
• Acute hepatitis, severe cirrhosis or liver tumors.

16. Mental condition rendering the patients unable to understand the nature, scope and possible consequences of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 39 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Khaled Afifi

Assistant lecturer of O&G

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mostafa Fouad, MD

Role: PRINCIPAL_INVESTIGATOR

Assistant Professor

Ahmed Abbas, MD

Role: STUDY_DIRECTOR

Lecturer

Locations

AinShams Maternity Hospital

Cairo, , Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Khaled Afifi, MSc

Role: CONTACT

DrKhaledAfifi@hotmail.com

01009981222

Facility Contacts

Khaled Afifi, MSc

Role: primary

DrKhaledAfifi@hotmail.com

01009981222

Other Identifiers

OCP-AntagonistPCOS

Identifier Type: -

Identifier Source: org_study_id